2nd treatment for EGFR+ NSCLC with exon 19 deletions or exon 21 L858R mutations
RYBREVANT® + chemotherapy reduced the risk of cancer growing or spreading by 52% compared with chemotherapy alone
At 6.3 months, half of the people receiving RYBREVANT® + chemotherapy lived without their cancer growing or spreading, compared with 4.2 months for chemotherapy alone.
These results are from a clinical trial where 394 people with advanced NSCLC with common received RYBREVANT® in combination with chemotherapy as a second treatment or received chemotherapy alone as a second treatment after the current standard of care (osimertinib*).
About the people in the clinical trial
- Most of the people never smoked (65%)
- Over half of the people were women (60%)
53% of people responded (tumors got smaller† or disappeared‡) with RYBREVANT® + chemotherapy
RYBREVANT® + chemotherapy
Tumors got smaller†: 52%
Tumors disappeared‡: 1%
Chemotherapy alone
Tumors got smaller†: 29%
Tumors disappeared‡: 0%
Of people who responded, half were still responding at 6.9 months with RYBREVANT® + chemotherapy and 5.6 months with chemotherapy alone.
Chemotherapy = carboplatin + pemetrexed
*Osimertinib is a preferred first treatment option for EGFR exon 19 deletion or exon 21 L858R in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines©)
†Tumors getting smaller may also be called a partial response. This means the tumor got measurably smaller but is still detectable.
‡Tumors disappearing may also be called a complete response. This does not necessarily mean the cancer has been cured.
Referenced with permission from the NCCN Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.10.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed September 25, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Side effects
There are side effects that you may experience during treatment with RYBREVANT®.
Savings & Support
Once prescribed a RYBREVANT®-based treatment, connect with a Care Navigator for your support needs.
The support and resources provided by RYBREVANT withMe are not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.
EGFR = epidermal growth factor receptor; NSCLC = non–small cell lung cancer